CoChat
Sign Up
Cited by 93

The DOI matches its Crossref record.

The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane

Berndt, N, Yang, H, Trinczek, B, Betzi, S, Zhang, Z, Wu, B, Lawrence, N J, Pellecchia, M, Schönbrunn, E, Cheng, J Q, Sebti, S M·2010·Cell Death & Differentiation
DOI 10.1038/cdd.2010.63PMC PMC2952662
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2010.63

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Triciribine phosphate exerts its kinase inhibitory effect by binding to the PH domain of AKT, thereby preventing its recruitment to the plasma membrane.

    “Triciribine phosphate exerts it kinase inhibitory effect by binding to the PH domain of AKT, thereby preventing its recruitment to the plasma membrane24.”

    From Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA (2018) · cites this paper as [24]

    The Abstract and Discussion state that TCN-P binds the Akt PH domain and prevents Akt recruitment to the plasma membrane, leading to reduced Akt phosphorylation. But the Results explicitly find that TCN-P does not directly inhibit Akt kinase activity in vitro; the paper describes it as an Akt activation inhibitor, not a direct kinase inhibitor. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 41

  1. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA . Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 1991; 88: 4171–4175. · DOI
  2. Coffer PJ, Woodgett JR . Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991; 201: 475–481. · DOI
  3. Bellacosa A, Testa HR, Staal SP, Tsichlis PN . A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254: 274–277. · DOI
  4. Manning BD, Cantley LC . AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261–1274. · DOI · Paper page
  5. Qiao M, Sheng S, Pardee AB . Metastasis and AKT activation. Cell Cycle 2008; 7: 2991–2996. · DOI
  6. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev 2001; 15: 2203–2208. · DOI
  7. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ . Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001; 276: 38349–38352. · DOI
  8. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu QW, Crenshaw Iii EB et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 2001; 292: 1728–1731. · DOI
  9. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS et al. Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol Cell Biol 2005; 25: 1869–1878. · DOI
  10. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997; 7: 261–269. · DOI
  11. Feng J, Park J, Cron P, Hess D, Hemmings BA . Identification of a PkB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004; 279: 41189–41196. · DOI
  12. Bozulic L, Surucu B, Hynx D, Hemmings BA . PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30: 203–213. · DOI
  13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the Rictor–mTOR complex. Science 2005; 307: 1098–1101. · DOI · Paper page
  14. Alessi DR, Andjelkovic M, Caudwell FB, Cron P, Morrice N, Cohen P et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541–6551. · DOI
  15. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K et al. Protein phosphatase 2A negatively regulates Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 2004; 24: 8778–8789. · DOI
  16. Xu W, Yauan X, Jung YJ, Yang Y, Basso AD, Rosen N et al. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003; 63: 7777–7784.
  17. Brognard J, Newton AC . PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 2008; 19: 223–230. · DOI
  18. Dillon RL, White DE, Muller WJ . The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007; 26: 1338–1345. · DOI
  19. Liu W, Bagaitkar J, Watabe K . Roles of AKT in breast cancer. Front Biosci 2007; 12: 4011–4019. · DOI
  20. Sun M, Wang J, Pacigga JE, Feldman RI, Yuan Z-Q, Ma X-L et al. Akt1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431–437. · DOI
  21. Sun M, Paciga JE, Feldman RI, Yuan Z-Q, Coppola D, Lu YY et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res 2001; 61: 5985–5991.
  22. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439–445. · DOI
  23. Liu X, Shi Y, Han EK, Chen Z, Rosenberg SH, Giranda VL et al. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 2001; 3: 278–286. · DOI
  24. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Auyala R et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003; 63: 196–206.
  25. Stahl JM, Sharma A, Cheung M, Zimmermann M, Cheng JQ, Bosenberg MW et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002–7010. · DOI
  26. Liang J, Slingerland JM . Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339–345. · DOI · Paper page
  27. Bozulic L, Hemmings BA . PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009; 21: 256–261. · DOI
  28. Gonzalez E, McGraw TE . The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009; 8: 2502–2508. · DOI
  29. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV . The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005; 24: 7482–7492. · DOI
  30. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB . Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988–1004. · DOI
  31. Yang L, Dan HC, Sun M, Liu QY, Sun XM, Feldman RI et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64: 4394–4399. · DOI · Paper page
  32. Schweinsberg PD, Smith RG, Loo TL . Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981; 30: 2521–2526. · DOI · Paper page
  33. Wotring LL, Crabtree GW, Edwards L, Parks Jr RE . Mechanism of activation of triciribine phosphate (TCN-P) as a prodrug form of TCN. Cancer Treat Rep 1986; 70: 491–497.
  34. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ et al. Phase I pharmacodynamic study of triciribine phosphate, a small molecule inhibitor of Akt phosphorylation, in adult subjects with solid tumors containing phosphorylated Akt In: 10th Annual AACR Meeting Denver, CO, 2009. · DOI
  35. Hiromura M, Okada F, Obata T, Auguin D, Shibata T, Roumestand C et al. Inhibition of Akt kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem 2004; 279: 53407–53418. · DOI
  36. Thomas CC, Deak M, Alessi DR, van Aalten DM . High-resolution structure of the pleckstrin homology domain of protein kinase b/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 2002; 12: 1256–1262. · DOI
  37. Auguin D, Barthe P, Auge-Senegas MT, Stern MH, Noguchi M, Roumestand C . Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates. J Biomol NMR 2004; 28: 137–155. · DOI
  38. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998; 17: 313–325. · DOI
  39. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159–168. · DOI · Paper page
  40. Fukuda T, Guo L, Shi X, Wu C . CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt. J Cell Biol 2003; 160: 1001–1008. · DOI
  41. Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009; 8: 1940–1951. · DOI

Cited by

Sorted by citations

Metadata

Authors
Berndt, N., Yang, H., Trinczek, B., Betzi, S., Zhang, Z., Wu, B., Lawrence, N. J., Pellecchia, M., Schönbrunn, E., Cheng, J. Q., & Sebti, S. M.
Venue
Cell Death & Differentiation
Publisher
Springer Science and Business Media LLC
Published
2010-05-21
Volume
17
Issue
11
Pages
1795-1804
ISSN
  • 1350-9047
  • 1476-5403
DOI
10.1038/cdd.2010.63
PMC
PMC2952662
Cited by
93
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review